Repaglinide 2 MG tablet 90S
Ended Awarded Last action
- Contract number
- SPE2DR26FCFQ8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $47,506
Award facts
- Contract value 100% obligated
- $47,505.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $47,505.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Repaglinide 2 mg tablets in quantities of 90 units. This firm fixed-price delivery order, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was issued without subcontractor involvement and represents one of numerous delivery orders DMS Pharmaceutical Group has received from the Defense Logistics Agency's Medical Supply Chain division.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, awarded in November 2025 with a $499,999,999 ceiling value and completion date of December 31, 2036, positions DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. This contract structure authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support military healthcare facilities worldwide, with DMS Pharmaceutical Group's established performance demonstrating its capability to fulfill the specialized pharmaceutical requirements of the Department of Defense medical system.
Quick answers
Who was awarded contract SPE2DR26FCFQ8?
SPE2DR26FCFQ8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FCFQ8 worth?
The government has obligated $47,506 on SPE2DR26FCFQ8.
Is contract SPE2DR26FCFQ8 an order under another contract?
Yes. SPE2DR26FCFQ8 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFQ8 competed?
The extent of competition for SPE2DR26FCFQ8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award